SELLAS Life Sciences (SLS) Shares Outstanding (Diluted Average) (2012 - 2026)

SELLAS Life Sciences (SLS) has 12 years of Shares Outstanding (Diluted Average) data on file, last reported at $172.5 million in Q1 2026.

• Quarterly Shares Outstanding (Diluted Average) rose 96.54% year-over-year to $172.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $172.5 million (up 96.54% YoY) and the FY2025 annual result came in at $109.1 million, up 78.18% from the prior year.
• Shares Outstanding (Diluted Average) climbed to $172.5 million in Q1 2026 per SLS's latest filing, from $109.1 million in the prior quarter.
• Across five years, Shares Outstanding (Diluted Average) topped out at $172.5 million in Q1 2026 and bottomed at $15.9 million in Q1 2022.
• The 5-year median for Shares Outstanding (Diluted Average) is $44.8 million (2024), against an average of $57.0 million.
• The widest annual swing landed in 2022, when Shares Outstanding (Diluted Average) grew 6.86%; it then jumped 121.99% in 2024.
• Tracing SLS's Shares Outstanding (Diluted Average) over 5 years: stood at $19.4 million in 2022, then surged by 43.21% to $27.8 million in 2023, then soared by 120.33% to $61.2 million in 2024, then soared by 78.18% to $109.1 million in 2025, then jumped by 58.17% to $172.5 million in 2026.
• Per Business Quant, the three latest SLS Shares Outstanding (Diluted Average) figures stand at $172.5 million (Q1 2026), $109.1 million (Q4 2025), and $98.3 million (Q3 2025).

Peer Comparison